2018 Á¾¾ç¸é¿ª´ÙÇÐÁ¦¿¬±¸È¸ Ãß°è½ÉÆ÷Áö¾ö (MSIO Fall Conference) : 2018-10-12±³À°ÀÏÀÚ : 2018-10-12
±³À°Àå¼Ò : ÀÓÆ丮¾óÆ縮½ºÈ£ÅÚ 7Ãþ µÎº£È¦
±³À°ÁÖÁ¦ :
2018 Á¾¾ç¸é¿ª´ÙÇÐÁ¦¿¬±¸È¸ Ãß°è½ÉÆ÷Áö¾ö (MSIO Fall Conference) ÁÖÃÖ±â°ü : ´ëÇÑÆó¾ÏÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : Á¾¾ç¸é¿ª´ÙÇÐÁ¦¿¬±¸È¸
´ã´çÀÚ : ½É¹Î°æ
¿¬¶ôó : 02-741-8540
À̸ÞÀÏ :
kalc@lungca.or.kr ±³À°Á¾·ù : ³»°ú, ÈäºÎ¿Ü°ú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, º´¸®°ú, °¡Á¤ÀÇÇаú
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 6 ½Ã°£ 35ºÐ
¼¼ºÎ¼ö°·á : 80,000¿ø
ºñ°í »çÀüµî·Ï ȸ¿ø: 50,000 ºñȸ¿ø 70,000 ÇöÀåµî·Ï ȸ¿ø: 60,000 ºñȸ¿ø 80,000
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 10¿ù 12ÀÏ µÎº£È¦ 09:00~09:20 Current controversies and future perspectives in immuno-oncology biomarker testing ±èÈ¿Áø(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10¿ù 12ÀÏ µÎº£È¦ 09:20~09:40 Beyond PD-L1: Who will get benefit from checkpoint inhibitors? ±èÀº°æ(BMS)
±³À°½Ã°£ 10¿ù 12ÀÏ µÎº£È¦ 09:40~10:00 Genomic biomarkers for cancer immunotherapy ½ÉÈ¿¼·(¿¬¼¼ÀÇ´ë)
Åä·Ð 10¿ù 12ÀÏ µÎº£È¦ 10:00~10:10 Åä·Ð ()
±³À°½Ã°£ 10¿ù 12ÀÏ µÎº£È¦ 10:10~10:55 Evolution of Immunotherapy Decision-Making for Non-Small Cell Lung Cancer David R. Gandara(UC Davis Comprehensive Cancer Center)
ÈÞ½Ä 10¿ù 12ÀÏ µÎº£È¦ 10:55~11:15 ÈÞ½Ä ()
±³À°½Ã°£ 10¿ù 12ÀÏ µÎº£È¦ 11:15~11:45 Dealing with adverse events of immunotherapy : Case ÀÓ¼±¹Î(Â÷ÀÇ°ú´ë)
±³À°½Ã°£ 10¿ù 12ÀÏ µÎº£È¦ 11:45~12:15 Multiple choice questions, but one decision ÀÌÀ±±Ô(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 10¿ù 12ÀÏ µÎº£È¦ 12:15~13:00 Immune check point inhibitors in advanced NSCLC: Patient selection, Successes and challenges Á¶Àº°æ(°¡ÃµÀÇ´ë)
ÈÞ½Ä 10¿ù 12ÀÏ µÎº£È¦ 13:00~13:15 ÈÞ½Ä ()
±³À°½Ã°£ 10¿ù 12ÀÏ µÎº£È¦ 13:15~14:00 Applying Advances in Genetics and Immunology to Develop Effective Immunotherapy for NSCLC Regardless of Tumor Mutational Burden Bernard A. Fox(Earle A Chiles Research Institute Robert W. Franz Cancer Center)
±³À°½Ã°£ 10¿ù 12ÀÏ µÎº£È¦ 14:00~14:20 Plasticity of innate lymphoid cells (ILCs) in tumor microenvironment Á¤µÎÇö(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10¿ù 12ÀÏ µÎº£È¦ 14:20~14:40 Immuno-biology of immune checkpoint receptors ÇÏ»óÁØ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10¿ù 12ÀÏ µÎº£È¦ 14:40~15:00 Immunological techniques in the study of human T cells Á¤¹Î°æ(KAIST)
Åä·Ð 10¿ù 12ÀÏ µÎº£È¦ 15:00~15:10 Åä·Ð ()
ÈÞ½Ä 10¿ù 12ÀÏ µÎº£È¦ 15:10~15:30 ÈÞ½Ä ()
±³À°½Ã°£ 10¿ù 12ÀÏ µÎº£È¦ 15:30~15:50 Issues of Immune Checkpoint Inhiibitors as Neo-adjuvant and Adjuvnat Therapy; Surgeon's View ±èÈ«°ü(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 10¿ù 12ÀÏ µÎº£È¦ 15:50~16:10 Issues of Immune Checkpoint Inhibitors as Concurrent and Consolidation Therapy: Radiation Oncologist's View ¼Û½Ã¿(¿ï»êÀÇ´ë)
±³À°½Ã°£ 10¿ù 12ÀÏ µÎº£È¦ 16:10~16:30 Artificial intelligence, role as a clinical decision support system ¹Ú°Ç¿í(°è¸íÀÇ´ë)